• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Ascentage Pharma Group International

    4/21/25 9:20:58 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAPG alert in real time by email
    6-K 1 ea0238938-6k_ascentage.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of April 2025

     

    Commission File Number: 002-023311

     

    ASCENTAGE PHARMA GROUP INTERNATIONAL

    (Translation of Registrant’s name into English)

     

    68 Xinqing Road

    Suzhou Industrial Park

    Suzhou, Jiangsu

    China

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒        Form 40-F ☐

     

     

     

     

     

     

    On April 21, 2025, Ascentage Pharma Group International issued a Hong Kong Stock Exchange voluntary announcement entitled “ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX AND OLVEREMBATINIB IN CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) 2025 GUIDELINES”.

     

    A copy of the Hong Kong Stock Exchange voluntary announcement is attached as Exhibit 99.1 to this Form 6-K and is incorporated by reference herein.

     

    1

     

     

    INDEX TO EXHIBITS

     

    Exhibit Number   Exhibit Title
         
    99.1   Hong Kong Stock Exchange voluntary announcement dated April 21, 2025

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      ASCENTAGE PHARMA GROUP INTERNATIONAL
         
    Date: April 21, 2025 /s/ Dajun Yang
      Name: Dajun Yang
      Title: Chief Executive Officer

     

    3

     

    Get the next $AAPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AAPG

    DatePrice TargetRatingAnalyst
    3/27/2025Overweight
    Analyst
    More analyst ratings

    $AAPG
    SEC Filings

    See more
    • SEC Form 6-K filed by Ascentage Pharma Group International

      6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

      4/28/25 5:13:19 PM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by Ascentage Pharma Group International

      6-K/A - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

      4/24/25 7:30:08 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Ascentage Pharma Group International

      6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

      4/21/25 9:20:58 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AAPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Ascentage Pharma

      Analyst initiated coverage of Ascentage Pharma with a rating of Overweight

      3/27/25 8:09:51 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AAPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

      ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it has presented results from five preclinical studies during poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois, USA. These poster presentations feature five of the company's drug candidates: novel tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351), Bcl-2 inhibitor lisaf

      4/28/25 7:00:00 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

      ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical studies of the Bcl-2 selective inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations will include an oral report featuring upd

      4/23/25 7:00:40 PM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

      ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company's investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company's novel next-generation t

      4/21/25 7:00:07 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AAPG
    Financials

    Live finance-specific insights

    See more
    • Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

      ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he

      3/12/25 8:46:58 AM ET
      $AAPG
      Biotechnology: Pharmaceutical Preparations
      Health Care